Compositions and methods to modify cells for therapeutic objectives
US-2016145348-A1 · May 26, 2016 · US
Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
US12030952B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12030952-B2 |
| Application number | US-202217664609-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 23, 2022 |
| Priority date | Oct 2, 2015 |
| Publication date | Jul 9, 2024 |
| Grant date | Jul 9, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.
First claim
Opening claim text (preview).
What is claimed is: 1. A bispecific antibody binding to human CD20 and human transferrin receptor comprising: a first light chain comprising the amino acid sequence of SEQ ID NO: 01, a first heavy chain comprising the amino acid sequence of SEQ ID NO: 02, a second light chain comprising the amino acid sequence of SEQ ID NO: 03, and a second heavy chain comprising the amino acid sequence of SEQ ID NO: 10. 2. The antibody of claim 1 , wherein the antibody comprises two copies of the first light chain, one copy of the first heavy chain, one copy of the second light chain, and one copy of the second heavy chain. 3. The antibody of claim 1 , wherein the antibody is monoclonal. 4. A pharmaceutical formulation comprising the antibody of claim 1 and a pharmaceutically acceptable carrier. 5. A pharmaceutical composition comprising the antibody of claim 2 and a pharmaceutically acceptable carrier. 6. A method of treating an individual having multiple sclerosis, comprising administering to the individual an effective amount of the antibody of claim 1 . 7. A method of depleting brain sequestered B-cells expressing CD20 in an individual, comprising administering to the individual an effective amount of the antibody of claim 1 to deplete brain sequestered B-cells expressing CD20. 8. The method of claim 6 , wherein the individual has primary progressive multiple sclerosis. 9. The method of claim 6 , wherein the individual has secondary progressive multiple sclerosis. 10. The method of claim 6 , wherein the individual has relapsing remitting multiple sclerosis.
Assignees
Inventors
Classifications
specific for leukemia · CPC title
Antineoplastic agents · CPC title
comprising antibodies · CPC title
multispecific · CPC title
against CD71 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12030952B2 cover?
- Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.
- Who is the assignee on this patent?
- Hoffmann La Roche
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2887. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).